Goldline Pharmaceutical SME IPO Review
Goldline Pharmaceutical SME IPO is yet to receive analyst coverage — analyst reports and verdicts will be updated here as and when they are published. The IPO is priced in the band of ₹41-43 per share with a minimum lot size of 3000 shares (minimum investment of ₹129,000) . Subscription opens on 12 May 2026 and closes on 14 May 2026. In the meantime, you can track the live GMP and subscription status for early market signals.
Table of Contents
Latest IPO Reviews
Frequently Asked Questions
Should I apply for Goldline Pharmaceutical SME IPO?
Analyst coverage for Goldline Pharmaceutical SME IPO has not been published yet. Analyst verdicts will be updated here as they come in — check back closer to the subscription dates.
What does the score of N/A mean for Goldline Pharmaceutical SME IPO?
Analyst scoring is not yet available for Goldline Pharmaceutical SME IPO. The score will be updated once analyst reports start coming in.
What are the listing gain expectations for Goldline Pharmaceutical SME IPO?
Grey market data is not yet available for Goldline Pharmaceutical SME IPO. As the subscription period approaches, GMP signals typically start forming. Check the GMP page for the latest updates.
What is the price band and lot size of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO is priced at ₹41-43 per share. The minimum lot size is 3000 shares, making the minimum investment approximately ₹129,000 at the upper end of the price band. The subscription window is open from 12 May 2026 to 14 May 2026.
Explore Goldline Pharmaceutical SME IPO Further
Track every stage of this IPO:
Discussion 0
No comments yet
Be the first to share your thoughts!